Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma

This study has been terminated.
(Low accrual rate)
Dana-Farber Cancer Institute
Brigham and Women's Hospital
Massachusetts General Hospital
Genzyme, a Sanofi Company
Information provided by (Responsible Party):
Patrick Y. Wen, MD, Dana-Farber/Brigham and Women's Cancer Center Identifier:
First received: April 6, 2011
Last updated: September 21, 2016
Last verified: September 2016
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: January 2017
  Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)